Review Article

H2A.X Phosphorylation in Oxidative Stress and Risk Assessment in Plasma Medicine

Clarissa S. Schütz, 1 Matthias B. Stope, 2 and Sander Bekeschus 3

1 Clinic and Polyclinic of Urology, Greifswald University Medical Center, Sauerbruchstr., 17475 Greifswald, Germany
2 Clinic and Polyclinic of Gynecology and Gynecological Oncology, Bonn University Medical Center, Venusberg-Campus 1, 53127 Bonn, Germany
3 ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany

Correspondence should be addressed to Sander Bekeschus; sander.bekeschus@inp-greifswald.de

Received 3 August 2021; Accepted 3 November 2021; Published 13 December 2021

Academic Editor: Antonello Lorenzini

Copyright © 2021 Clarissa S. Schütz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

At serine 139-phosphorylated gamma histone H2A.X (γH2A.X) has been established over the decades as sensitive evidence of radiation-induced DNA damage, especially DNA double-strand breaks (DSBs) in radiation biology. Therefore, γH2A.X has been considered a suitable marker for biomedical applications and a general indicator of direct DNA damage with other therapeutic agents, such as cold physical plasma. Medical plasma technology generates a partially ionized gas releasing a plethora of reactive oxygen and nitrogen species (ROS) simultaneously that have been used for therapeutic purposes such as wound healing and cancer treatment. The quantification of γH2A.X as a surrogate parameter of direct DNA damage has often been used to assess genotoxicity in plasma-treated cells, whereas no sustainable mutagenic potential of the medical plasma treatment could be identified despite H2A.X phosphorylation. However, phosphorylated H2A.X occurs during apoptosis, which is associated with exposure to cold plasma and ROS. This review summarizes the current understanding of γH2A.X induction and function in oxidative stress in general and plasma medicine in particular. Due to the progress towards understanding the mechanisms of H2A.X phosphorylation in the absence of DSB and ROS, observations of γH2A.X in medical fields should be carefully interpreted.

1. Introduction

Since phosphorylated gamma histone H2A.X (γH2A.X) occurs rapidly, abundantly, and stoichiometrically with the frequency of DNA double-strand breaks (DSBs), γH2A.X has proven itself as a recognized indicator for radiation-induced DSBs in particular and direct DNA damage in general [1]. Proceeding from this proportionality in radiobiology, γH2A.X was used as a DNA-associated biomarker and a direct correlate of DSBs in different studies testing chemical and physical treatments, for instance, in the field of oncology [2, 3].

In addition to the oxidative, via reactive oxygen species (ROS-) induced DNA damage response (DDR), cold physical plasma presents an innovative, promising concept in antitumor therapy [4–6]. A multicomponent system, cold plasma consists of physical emitters, such as ultraviolet (UV) and thermal radiation, and biological-chemical components, including charged particles and various reactive oxygen and nitrogen species (ROS/RNS) [7]. The anticancer effect of medically accredited plasma jet devices [8] has already been proven to a limited extent in small cohort studies in clinical settings of palliation and precancerous [9–11]. Accompanying plasma-induced apoptosis, phosphorylation of H2A.X was observed in an array of in vitro studies [12–31]. These findings led to the hypothesis that direct (oxidative) damage of DNA results from plasma-generated primary ROS [32]. However, in terms of its cellular effect, cold plasma is confirmed as nongenotoxic and nonmutagenic as studies in vitro, in vivo, and long-term follow-up patients suggest [33–36]. This apparent difference calls for a closer look at γH2A.X in cold plasma treatment, where
ROS/RNS are generated extracellularly in contrast to known mutagenic agents such as UV and ionizing radiation (IR) generating radicals directly at the DNA.

Cell metabolism, oxidative stress, DNA damage, and apoptosis are often closely related to H2A.X phosphorylation and have not yet been sufficiently investigated independently to characterize the γH2A.X induction as a function of the plasma treatment. For instance, the cytostatic drug doxorubicin induces DSBs and ROS-mediated oxidative stress leading to H2A.X phosphorylation [37]. As shown in numerous studies, damaged DNA and phosphorylated H2A.X correlate. However, this only applies unidirectionally: every DSB results in H2A.X phosphorylation. Yet, the reverse conclusion that every γH2A.X can be traced back to the presence of a DNA DSB is not permissible [38, 39]. Several studies postulate the cause-effect-consequence relationship that primary ROS (cause), generated exogenously after cold plasma treatment, induce DNA damage directly (effect) marked by nuclear γH2A.X (consequence) [13, 15, 20, 25, 32]. Questionable about this causal relationship is whether plasma-mediated ROS after diffusion through the cell membrane, cytosol, and membranes of endoplasmic reticulum (ER) and the nucleus—not to mention the numerous antioxidant enzymes with exceedingly high rate constants towards ROS [40]—are still able to reach DNA to mediate damage directly. Since, apart from the H2A.X phosphorylation, there is no evidence of cold plasma-associated cytogenetic and intranuclear DNA damage, further clarification of the molecular mechanisms on cells and the γH2A.X induction is required to assess the suitability γH2A.X in plasma medical research.

2. Histone γH2A.X

2.1. Biochemistry. In eukaryotic nuclei, the DNA and DNA-binding proteins and histones form nucleosomes as functional units of the higher-level chromatin complexes (Figure 1) [41]. The crystallographic structure of such a nucleosome comprises 145 to 147 base pairs (bp) of DNA [42], wound as a superhelix around a histone octamer composed of heterodimers from each of the four histone families: H2A, H2B, H3, and H4. Two tetramers, (H2A-H2B)_2 and (H3-H4)_2, form the nucleosome core particle [43, 44]. Several genes encode the histones of each family expressed as cell cycle-dependent during DNA replication in the S phase [45]. The histone family H2A as an essential component of chromatin is divided into the members H2A.1-H2A.2, H2A.X, and H2A.Z, of which H2A.1-H2A.2 take the central part [46]. In eukaryotes, H2A.Z represents about 10% of the H2A, H2AX 2-10% in mammals, and larger fractions up to 25% in lower eukaryotes [2].

H2A.X consists of its primary structure of 142 amino acids and differs from the remaining members of the H2A family by a highly conserved 22 amino acid sequence at the C-terminus, called KATQAS′QEY-COOH, which is not related to any known domain in vertebrate histone H2A [43]. Within the tetrapeptide Ser_{139}-Gln_{140}-Glu_{141}-Tyr_{142} of the S′QEY-motif, histone H2A.X is posttranslationally modified. H2A.X can be phosphorylated C-terminally at position serine_{139} via an ester bond between a phosphate residue and the hydroxyl group (-OH) and is then called γH2A.X [44]. This phosphorylation as an early DDR component is catalyzed by the phosphotransferases ataxia telangiectasia mutated (ATM), the ataxia telangiectasia, and Rad3-related protein (ATR), and the DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) [47, 48]. As serine/threonine kinases, all three of them belong to the phosphoinositide 3-kinases (PI3K). Moreover, mitogen-activated protein kinases (MAPK) p38 and JNK are associated with the formation of γH2A.X [49–51]. PI3K and p38-MAPK are both activated by DNA lesions. Being imperative for a signaling system to perform, it must be possible to switch off the corresponding signals. For this, the H2A.X phosphorylation is reversed by the protein phosphatases PP2A, PP4C, and PP6 and the wild-type p53-induced phosphatase 1 (WIP1) [52, 53].

2.2. DDR Signaling. Living organisms are continuously exposed to a wide range of different DNA-damaging agents, affecting health, disease, mutagenesis, and malicious transformation up to cell death. In particular, tumor cells are often deficient in the DDR, so several antitumor therapies are based on the induction of genotoxicity [54]. While DNA single-strand breaks (SSBs) occur 50,000 times per human cell and day, oxidative base damage is less frequent at about 2,000, and intrastrand cross-links and DSBs occur 10 times per day [55]. For instance, direct DNA damage is caused by exogenous factors like UV and ionizing radiation, or ROS produced intracellularly by metabolic processes. A variety of repair mediators are integrated into the DNA damage- and ROS-induced cascade, such as p53 binding protein 1 (53BP1), the tumor suppressor gene product BReast CAncer (BRCA1), ATRIP, KU70/80, and NBS1/Mre11/Rad50 [56–58]. UVB light-emitting radiation between 290 and 315 nm modifies DNA directly by cross-linking between C and T or between two T bases inducing cyclobutene-pyrimidine dimers (CPD) by forming 6-4 photoproducts and inducing DNA single-strand breaks [59]. The SSB repair mechanism is orchestrated by the signaling complex ATR and ATRIP [56–58]. Ionizing radiation is one of the first exogenous agents involved in DSB induction. In response to a radiation-induced DSB, NBS1, Mre11, and Rad50 accumulate and colocalize with ATM and phosphorylated H2A.X [47]. A well-known mechanism upstream of the signaling cascade leading to the phosphorylation of H2A.X is the autophosphorylation of an ATM monomer at serine_{1981} as a result of a DSB [60]. Moreover, the DDR signaling pathway by DNA-PKcs is associated with the protein complex KU70/80 [47]. In one cell cycle, at least 5,000 SSBs are formed caused by endogenous ROS production, and overlapping SSBs lead to DSB formation [39]. Approximately 1% of single-strand breaks are transformed into double-strand breaks, while 99% are repaired impressively, reflecting the importance and efficiency of the cells’ DDR system to protect the DNA [61]. As a cellular response to detected DNA damage, a signaling transduction cascade follows in which the cell can be arrested temporarily via checkpoint
control activation and permanently by senescence in the cell cycle or in which cell death can be promoted [62].

While PI3K activation initially appears in response to a large number of DNA damage, phosphorylated H2A.X is instead responsible for the association of repair enzymes and signaling molecules, highlighting its diverse and pleiotropic function [57].

2.3. Pleiotropic Roles. In addition to its functional role in the nucleosome to ensure genomic stability, (γ)H2A.X has a specialized cellular function by signaling and initializing DNA repair [47, 62, 63]. The H2A.X phosphorylation is considered one of the first reactions in the cellular DDR, particularly to DNA DSBs, which are among the DNA lesions with the most pronounced cytotoxicity [64, 65]. γH2A.X has already been used as an indicator of apoptosis by chemotherapeutic agents and an early marker for DSBs in human lung adenocarcinoma cells A549 upon exposure to tobacco smoke [61, 66, 67]. The γH2A.X foci test was reported to identify DNA-damaging agents with the same specificity as the in vitro genotoxicity study standard, the cytokinesis-block micronucleus (MN) assay [68]. In addition to MN formation and mutation frequency, the phosphorylation of H2A.X is defined as one of three genotoxic endpoints. As a de novo modification of the histone H2A.X, γH2A.X has a greater degree of reliability in marking DSBs than other repair proteins present intracellularly even without a DNA lesion, such as 53BP1 [69]. The detection of H2A.X phosphorylation has a great potential in evaluating oncological therapeutic approaches in chemotherapy and radiation therapy. Phosphorylated H2A.X, more precisely the loss of γH2A.X, is suggested as an indicator of radiosensitivity [38, 70, 71].

The formation of γH2A.X is not limited to exposure to ionizing radiation [38]. Several other exogenous noxae lead to H2A.X phosphorylation. Physical factors include UV radiation, low pH, heat, and hypoxia [72–75]. Chemical toxins include DNA-damaging agents such as bleomycin, doxorubicin, and ROS [37]. Even without exogenous noxae, γH2A.X is formed during somatic V(D)J recombination to facilitate antibody variability in B cells or during DNA replication [76, 77]. As part of DNA fragmentation, γH2A.X is integrated into apoptosis, as apoptotic cells are γH2A.X-positive per se [14, 78]. Additionally, phosphorylated H2A.X acts as a tumor suppressor [62]. When employed as a biodosimeter, H2A.X phosphorylation also has relevance in aging research [79]. DSBs accumulate in senescent cells so that γH2A.X acts as an age marker. In turn, and even in the absence of a DSB, phosphorylated H2A.X occurs in mitotic sex chromosomes to form a condensed chromatin domain, the XY body [80]. In cancer research, quantifying γH2A.X evaluates not only the therapy’s effectiveness but also has the potential to detect precancerous lesions and to be a prognostic marker of tumor entities [57, 81, 82]. Here, the γH2A.X level reflects cancer-associated genomic instability of the nuclei [83].

**Figure 1:** Isoform histone H2A.X in the context of the chromatin structure. The nucleosome is made up of approximately 147 base pairs of DNA around a histone octamer. The core particle can contain instead of H2A.1-H2A.2 two proteins of H2A.X (H2A.X2) that are extended c-terminally by the S*QEY-motif of 22 amino acids. The functional group of the posttranslational phosphorylation to γH2A.X is the hydroxyl group (-OH) of the serine at position 139. Model adapted according to [44].
In addition to those pleiotropic roles, recent research suggests that the function of γH2AX is dispensable for the recruitment of DDR enzymes [84]. Neither the initial marking of a DSB nor the initial migration of repair mediators is canceled by the lack of phosphorylated H2AX so that γH2AX deficiency does not seem to be deleterious. Phosphorylated H2AX is said to connect the DDR and ROS signaling pathways [85]. Furthermore, both cascades are involved in apoptosis induction as a consequence of DNA damage. Here, DNA damage-associated γH2AX regulates Rac1/NOX1-mediated increase in intracellular ROS concentration [86]. A growing body of evidence supports the assumption that γH2AX occurrence in correlation or non-correlation with DNA lesions is far more complex. Generally, low quantities of H2AX phosphorylation are not associated with DNA DSBs [87]. Furthermore, γH2AX levels increase in untreated, normally proliferating cells when entering cell cycle mitosis (M phase) in the absence of a DNA-damaging agent and consequently any induction of a DDR [88]. This apparently suggests a physiological role of γH2AX apart from DNA damage. In nonstressed cells, downregulation of H2AX expression leads to damage in the mitochondria [89]. Moreover, the number of γH2AX foci in apoptotic cells is ten times higher than in nonapoptotic counterparts [90]. Ultimately, there are reports that ROS are responsible for γH2AX induction so that phosphorylated H2AX fulfills a potential role in redox signaling [60].

3. H2AX in Radiobiology

3.1. γH2AX Kinetics. The formation of DSBs in tumor cell DNA of tumor tissue is one of the detrimental effects of ionizing radiation, resulting in cell death. Being a biodosimeter in radiobiology, H2AX is modified within minutes proportionally to the IR intensity, and approximately 1% of all H2AX proteins is phosphorylated per gray irradiation [91]. One gray induces 35 DSBs per $6 \times 10^5$ bp of DNA in the G1 phase of the cell cycle, leading to H2AX phosphorylation distributed over 1% of the chromatin. According to this, about 0.03% of the chromatin, corresponding to $2 \times 10^8$ bp of DNA, are involved per DSB. Immunocytochemically, γH2AX can be explored using a phosphor-specific antibody targeting the phosphorylation of the C-terminal serine, in the form of so-called γH2AX foci [39, 92, 93]. It is well observed that the number of foci and radiation-induced DSBs are linked in a one-to-one manner so that the γH2AX assay is a validated tool for examining the correlation between the absorbed dose and biological effect in radiobiology [38, 47, 94].

It needs to be emphasized that phosphorylated H2AX should not be equated with γH2AX foci. As a DDR component, H2AX molecules are phosphorylated, flanking DNA damage sites. These domains with a local increase in the levels of phosphorylated H2AX can be detected by immunofluorescence as γH2AX foci [95]. Using different assays in cell biology, quantification of phosphorylated H2AX is often based on fluorescence read-out systems [39], and γH2AX measurements exhibit a wide range of numbers, sizes, and levels of phosphorylation [87]. While γH2AX foci visualized as bright dots in the nucleus are more specific to DSBs, phosphorylated H2AX respectively dim γH2AX foci are also observed in untreated cells. Notably, the H2AX phosphorylation level includes the DNA damage sites and free form of γH2AX if measured by global methods such as flow cytometry and western blotting. Hence, different findings might be obtained when comparing total vs. nuclear γH2AX levels, depending on the method used. Methods other than nuclear foci counting may tend to overestimate γH2AX levels related to DSBs. Moreover, a constitutive background expression of γH2AX gradually increases with cell aging towards senescence [96], while especially tumor cells express high endogenous levels, labeled as cryptogenic γH2AX [97, 98]. In addition, constitutive γH2AX levels are cell line and treatment agent-dependent [87], and foci formation and spreading at DNA damage sites is not static but dynamic [99, 100]. This is because foci expand over time so that many foci of lesser intensity generate approximately the same signal as a few intense ones. Thus, potential pitfalls to consider when troubleshooting γH2AX investigations are foci expansion with time, high background staining, or cytoplasmatic staining for phosphorylated H2AX. It was estimated that the relation of DNA damage-representing γH2AX foci and nonfoci-labeled γH2AX is 1 to 10 to up to 1 to 20 in untreated cells [39]. This also applies to UV radiation [101] and should be carefully considered when analyzing γH2AX. However, the agent- and dose-dependent nuclear-to-cytoplasmic ratio can be reversed, e.g., with IR [102]. Particularly for low doses, nuclear γH2AX foci represent the overall staining intensity well, while high doses may induce more pronounced cytoplasmatic foci staining. Adding to this complexity, a uniform widespread nuclear H2AX phosphorylation (pan-nuclear γH2AX) pattern can be observed especially in cells succumbing to replication stress [103].

3.2. Reports In Vitro and In Vivo. Because the response of eukaryotic cells to ionizing radiation is highly conserved and mediated by a DNA repair system characterized by early H2AX phosphorylation, the γH2AX foci detection is a well-established and sensitive assay to evaluate persistent DNA DSBs [70, 104]. Discussions on genotoxicological studies emphasized that phosphorylated H2AX has potential in the clinical setting, in particular, to determine the extent of DNA damage in patients undergoing radiotherapy [105]. However, radiation therapy is a modality of anticancer therapy and is vital in diagnostics, such as computer tomography. Hence, the investigation of γH2AX adjacent to the DSB is of great relevance [106]. In cell lines in vitro, phosphorylation of H2AX is a measure of radiosensitivity [107, 108]. Fast loss and less retention of γH2AX are therefore associated with increased radioresistance [38]. Hence, radiosensitive tumor cell lines retain phosphorylated H2AX longer than radioresistant counterparts, making the former more sensitive to apoptosis than the latter [102]. In addition to various cells in vitro, γH2AX detection was also used to quantify the effects of IR in tissues exposed ex vivo or in vivo [109, 110]. With a growing range of applications, γH2AX analysis expands beyond its traditional field of...
radiobiology, mainly because of its increasingly recognized role in ROS-related conditions.

3.3. Role of ROS in Radiotherapy. Radiotherapy damages living systems and tissues by directly damaging cellular targets and indirectly through water radiolysis, autoamplifying intranuclear ROS production. Similar to IR, UV, especially UVB radiation, can directly damage the DNA. The indirect action of UVB light is majorly mediated by ROS causing oxidative DNA damage, e.g., 8-hydroxy-2′-deoxyguanosine (8-OHdG). Unlike IR and UVB radiation, ROS/RNS need to travel from the gaseous to the liquid phase and eventually to the cells during plasma treatment. ROS accumulate in the extracellular space and at decreased levels in the intracellular environment after selective transit across the plasma membrane to interact with biomolecules in the cytosol.

UV radiation raises ROS levels both extracellularly and intracellularly [59, 118], physical plasma influences the cellular redox equilibrium via exclusively exogenously generated ROS, subsequently exerting oxidative stress intracellularly [119].

4. Plasma Medicine

4.1. Principle of Cold Physical Plasma. Physical plasma is the so-called fourth state of matter after solid, liquid, and gas. By definition, physical plasma is a multicomponent system made of, for instance, electric fields, electrons, ions, thermal and UV radiation, and ROS/RNS (Figure 3). During this phase transition from a gas to the plasma state, electrons are first excited before they dissociate from the atomic shell of the gas molecules. Freely moving electrons and ionized atoms increase the reactivity and electrical conductivity of physical plasmas [7]. With the emission of photons, excited particles return to the ground state, which causes the "plasma glow." The reactive particle mixture contains charged particles, for example, electrons and ions, excited atoms, and molecules [7, 120]. In addition, due to its ionizing effect and interaction with the surrounding air when operated under atmospheric pressure, physical plasma generates ROS/RNS such as O₃, H₂O₂, •OH, NO, HNO₃, O, and ONOO− [121–124]. Thermal movements, especially
heavy particles (ions), determine the gas temperature, whereby the plasma temperature correlates with the degree of ionization [7, 125]. In the nonthermal (cold) physical plasma, there is a thermal imbalance in which ions, in contrast to electrons, hardly experience any acceleration \( T_{\text{gas}} \approx T_{\text{ion}} < T_e \) in nonequilibrium plasmas) [7]. With temperatures below 40°C, cold plasma, which is described as partially ionized gas (one particle of \( 10^9 \) being ionized), has the greatest degree of tissue compatibility as it is operated at body temperature. The gas composition, gas humidity, and the surrounding environment are further factors influencing the effect of physical plasmas [122, 124, 126]. Cold plasma is usually generated by applying a high-frequency electrical voltage, and the main generation modes are dielectric barrier discharges (DBD) and jet plasmas [127, 128]. The utilization of cold physical plasma in the field of plasma medicine led to the coining of the term ‘plasma medicine.’

4.2. ROS/RNS Generation. While plasma acts physically across the spectrum of its emission, the chemical components, especially ROS/RNS, convey the plasma effects in biological systems. Initially, the cold plasma-derived ROS/RNS are generated exogenously in the gas phase [121]. The species then diffuse or penetrate the liquid cell environment, acting on proteins, lipids, nucleic acids, and other biomolecules. Notably, many cold plasma-generated ROS/RNS are similar to those species occurring in physiological processes, such as metabolism and antimicrobial defense. In vitro, where excess liquid dominates over cell-derived biomass, most short-lived plasma-derived ROS/RNS quickly react to more stable species, such as hydrogen peroxide (H\(_2\)O\(_2\)). Being a nonradical ROS, H\(_2\)O\(_2\) is an integral mediator of intracellular processes of oxidative eustress and distress, leading to signaling and growth stimulation on the one hand and cellular damage and apoptosis on the other [126, 129, 130]. Recently, the types, sources, gradients, and hormetic cellular effects of cold plasma-derived ROS/RNS in cells and tissues have been summarized [119]. Importantly, it has been noted early on that in vitro plasma-induced toxicity follows known processes in cell death research and redox biology [131]. Accordingly, coping with cold plasma-induced oxidative stress follows the concepts laid out by Helmut Sies, being a primary antioxidative protection system acting through enzymatic and nonenzymatic radical scavengers and antioxidants and a secondary system employing repair mechanisms of the DDR machinery [132]. Even if physical plasma is composed of UV radiation, charged particles, and other components, which may support a synergistic cytotoxic effect, extracellular generated ROS/RNS are the mediators of cold plasma cellular efficacy in the current understanding [133]. For the exogenously derived ROS/RNS to become effective, some species can penetrate cells through aquaporins and via diffusion as well.

---

**Figure 3:** Particle model of the three classical states of matter and active components of the nonclassical fourth state: physical plasma. In the solid state, atoms are held in their position by strong, attractive forces and form a rigid framework. When energy is supplied, the bonds break, the atoms lose their regular order, and the substance liquefies. With a further increase in energy, the atoms lose their cohesion and move freely in space in the gaseous state. Additional energy supply to a gas (ionization) creates gas in an excited state (plasma), a multicomponent system made up of physical and biological-chemical active components. Blue: ions; red: electrons.
as cholesterol-dependent lipid peroxidation [134]. Intracellular ROS/RNS influence the cascade of the second messenger calcium (Ca²⁺) and vice versa [135, 136]. Both ROS/RNS and calcium are involved in apoptosis signaling, and mitochondria and ER are organelles of crucial relevance. ROS-induced oxidative stress after cold plasma treatment leads to mitochondria oxidation, depolarization of the mitochondrial membrane potential (ΔΨm), and mitochondrial stress [131, 137]. It needs to be emphasized that scavenging exogenous cold plasma-derived ROS/RNS abrogates mitochondrial responses [138], demonstrating the lack of intracellularly generated ROS/RNS with plasma treatment. Moreover, at the ER, plasma-derived ROS cause an overload of calcium in the cytosol and promote ER stress [139]. Via a distinct region called mitochondria-associated ER membranes, the ER is reversibly bound to mitochondria, and the ER stress results in a calcium influx into mitochondria, eventually decreasing the membrane potential [140]. As a result of the ΔΨm collapse, the mitochondria disintegration with the subsequent release of cytochrome c triggers apoptosis induction [141].

4.3. Therapeutic Successes. The generation of cold plasma has recently developed into an innovative and attractive research field, and its application is the subject of different industries, especially in biophysics, plasma science, and medicine [142]. Physical plasmas are used to modify biorelevant surfaces, for decontamination purposes, and during argon (hot) plasma coagulation to provide hemostasis via cauterization [143, 144]. Moreover, cold physical plasmas at tissue-tolerable temperatures of around 40°C are used therapeutically and directly on the body surfaces due to their antibacterial, anti-inflammatory, and wound healing properties [145]. Other promising fields of application are expected in plastic surgery, oral medicine, and ophthalmology [146–148]. Oncology is an emerging treatment modality with great potency to convey synergy in the multimodal concept of antitumor therapy [6, 149, 150]. The assumption that cold plasma treatment induces apoptosis in cancer cells is supported by observations of various in vitro and in vivo [151–153]. However, a recent large-scale study across 35 cancer lines has shown up to 100-fold differences in the sensitivity of tumor cell lines towards cold plasma [154]. ROS of adequate concentration generally mediates a tumor-suppressive effect, which is used in the medical application of cold plasma in particular. Because cold plasma can interact with the tumor microenvironment, the plasma-mediated modulation of immune cells is of specific interest [155, 156].

Already before the recent COVID-19 crisis, several studies had examined the efficacy of cold plasma against viral agents along with plasma devices and design concepts for both sanitation and treatment [157]. A plasma source often used in biomedical research of plasma medicine is the plasma jet kINPen, which is operated at atmospheric pressure and consists of a pin electrode in the center of a dielectric capillary and a grounded outer electrode (Figure 4) [158]. Recently, the molecular mechanisms of cold plasma-induced effects were studied more extensively with the kIN-Pen and other cold plasma sources, especially in the light of safety assessment and DNA damage.

5. γH2A.X in Plasma Medicine

5.1. Summary of Findings. A growing body of literature observed a DDR after cold plasma treatment, including recruitment of ATM, H2A.X respectively γH2A.X, and p53. In the light of the pleiotropic roles of γH2A.X, this led to the misleading conclusion that plasma is mutagenic by causing primary DNA damage in the form of DSBs in living cells [14]. Cold plasma-induced γH2A.X was demonstrated cell type-independent in several cold plasma devices (Table 1) [12, 13, 15–28]. These studies contrast with the results on γH2A.X quantifications in human and porcine skin and oral mucosa ex vivo as well as in vitro genotoxicity and mutagenicity tests according to the OECD (Organization for Economic Co-operation and Development) guideline, none of which had shown any permanent DNA damage after cold plasma exposure [29–31, 33, 34, 159]. So far, only a few investigations in plasma medicine have examined the incidence of cytogenetic damage in cells and tissues using non-γH2A.X assays. However, these observations align with the potentially cytotoxic but neither DNA-damaging nor lasting mutagenic effects of cold plasma [160]. In contrast to UVB radiation, cold plasma-induced γH2A.X did not lead to significantly elevated micronucleus induction, while a correlation between both markers is frequently observed in the field of radiobiology [161, 162]. The lack of a significant increase in the micronuclear frequency as a functional surrogate of genotoxic DSBs is a necessary and sufficient criterion for the hypothesis that cold plasma in plasma medicine has except for—or despite—the H2A.X phosphorylation no sustained genotoxic or mutagenic effect [14, 34]. While this more recent work questioned the unambiguous correlation between γH2A.X and DNA DSBs, the majority of γH2A.X examinations in plasma medicine did not discuss the observation critically that cold plasma-mediated γH2A.X induction does not correlate to DSBs-related MN and do not take into account the interdependence of plasma-generated ROS and phosphorylated H2A.X [87]. Even if the reactive species of intrinsic versus plasma-produced ROS and their cellular targets are fundamentally identical, the theory of plasma-derived ROS directly damaging DNA marked by phosphorylated H2A.X raises doubts at several points along the ROS pathway from extracellular space to the nuclear DNA as explained below (Figure 4). Firstly, cold plasma generates ROS/RNS in the gas phase penetrating the liquid cell environment as an additional barrier to the direct plasma-cell-interaction consisting of an antioxidant system. Moreover, the ROS density produced by the plasma source changes with distance from the active plasma zone. Thus, reaching the cell from the outside, the effects of intracellularly occurring and plasma-derived ROS cannot be assumed to be congruent [122, 126]. Secondly, due to their species-specific reactivity, charge, polarity, and short lifetime, only a fraction of the primary extracellular produced ROS can pass through the plasma membrane, either by passive diffusion or by
facilitated processes via transporters or channels, for instance, the H₂O₂ transport through aquaporins [163, 164]. Not only the capacity of the transmembrane transport is limited but also the passage depends on the plasma membrane composition, especially on the cholesterol level [134]. Thirdly, the intracellular milieu offers opportunities for interactions between ROS and numerous reactants and ROS scavengers, including catalase, glutathione, NADPH+H⁺, and peroxiredoxins, which intercept with the ROS on their 2 to 10 μm long cytoplasmatic diffusion pathway from the cell membrane to the nucleus and decrease ROS level [165, 166]. Only stable ROS/RNS such as H₂O₂, nitrite, nitrate, and superoxide can passively diffuse across such distances. Notably, H₂O₂ is a sturdily nonreactive molecule and reacts with H₂O₂-deteriorating enzymes residing at high concentrations in the cytosol 100–1,000 times faster than passive protein oxidation [167]. Fourthly, the remaining ROS must pass through multiple cell organelles and membranes of the ER and ultimately the nucleus. It is unclear how short-lived, reactive species will travel through such protein and lipid-rich environments without finding reaction partners. Fifthly, in the unlikely event such species would make it to the nucleus, there are again antioxidant systems in place in the nucleus to protect against oxidative damage, such as peroxiredoxins 2 (PRDX2) [168]. The argument that H₂O₂ could make such travels undisturbed to generate hydroxyl radicals in the Fenton reaction is defective due to the cell’s lack of free iron pools. Conversely, iron is bound to storage and proteins, such as ferritin [169]. Moreover, if H₂O₂ and not the short-lived cold plasma-derived ROS/RNS would be responsible for DNA damage, it is not cold plasma that is mutagenic but H₂O₂. It should be kept in mind that endogenous H₂O₂ production during infection control can be exceedingly high, which would lead to the argument that inflammation in wound healing is mutagenic. Altogether, it seems unlikely that short-lived reactive species expelled by cold plasmas are stable and nonreactive enough to travel large distances intracellularly and undisturbed to perform the often-noted DNA-damaging effect.

5.2. Role of Signaling and Extracellular ROS. Considering the limitations of short-lived exogenous species directly traveling to the DNA to perform damage, the question remains why H2A.X induction is documented by many groups, including ours, following cold plasma treatment in vitro. In short, this is due to DNA damage-independent signaling, as the cell naturally activates its protection systems, including catalase, glutathione, NADPH+H⁺, and peroxiredoxins, attempts to counteract ROS. Intracellularly, ROS/RNS would have to pass through several structures and membranes of cell organelles, e.g., the ER, to eventually reach the nucleus. Finally, intranuclear antioxidant systems also offer protection from oxidative damage.
nor opportunity to discriminate between in the analysis of H2A.X phosphorylation responses.

The differentiation between H2A.X phosphorylation triggered by primary DNA damage and apoptosis-associated H2A.X phosphorylation as well as the kinetics of γH2A.X occurrence concerning its induction mechanisms. Fluorescence microscopy shows intranuclearly an apoptotic ring that includes H2A.X and DDR proteins in apoptotic cells [170]. Moreover, the γH2A.X presence resulting from a highly damaged DNA is divided into two phases: initially, rapid γH2A.X foci are formed; subsequently, apoptosis is initiated, and the γH2A.X-apoptotic ring is formed. Moreover, agents that do not primarily damage DNA and induce apoptosis, such as ligands of the extrinsic apoptosis initiation pathway or intrinsic stress, induce only the second sequence, the apoptotic ring. Theories about DNA damage by ROS are, on the one hand, a site-specific Fenton reaction and, on the other hand, an intracellular increase in calcium concentration, which in turn activates nucleases [171]. Even though γH2A.X is induced through oxidative stress and DNA can be damaged oxidatively, recent conclusions do not ascribe any primarily caused DNA damage in vitro to the plasma treatment [34, 160]. Moreover, even if lipid peroxidation would have a crucial role in facilitating the transmembrane passage and is a damage mechanism of high-grade oxidative stress, which can contribute to DNA lesions, the oxidative degradation of lipids should not be understood as a critical process of primarily caused DNA damage of exogenous ROS exposure [172–174]. Comparatively, low ROS concentrations and minor quantities of plasma-induced γH2A.X depending on catalase and pan-caspase inhibition refute lipid peroxidation as a potential mechanism for the DSB formation after exposure to plasma-derived ROS [14, 49]. Moreover, if lipid peroxidation were the DNA-damaging mechanism when applying low-dose ROS, the γH2A.X fluorescence should have increased independently of apoptosis and p38-MAPK signaling pathways, which was not the case in our recent study [14].

Although proliferating cells intrinsically have more damaged and unwound DNA owing to DNA and protein synthesis, it cannot be concluded that this makes them more susceptible to ROS-induced nuclear damage [72]. Moreover, albeit different studies formulating the idea that overlapping SSBs lead to DSBs and γH2A.X thus appears at the side of the initial DNA damage after such indirect DSB formation, the conclusion that extracellularly released ROS interact directly with the DNA leading to secondary damage seems less likely than the perspective of a ROS-initiated cytosolic signaling cascade, which results in H2A.X phosphorylation

| Table 1: Overview of γH2A.X studies in plasma medicine. Both using jet plasmas and dielectric barrier discharge (DBD) as a source of cold physical plasma, γH2A.X was quantified in vitro in low and high malignant cancer cell lines as well as ex vivo in cold plasma-treated tissue. |
|-----------------------------------------------|-------------------------------|-----------------|
| Low malignant cell line in vitro              | Plasma source | Reference       |
| HEK-293 (human embryonic kidney cells)       | Soft jet plasma | Kaushik et al. [12] |
| MRC-5 (human lung fibroblasts)                | Soft jet plasma | Kaushik et al. [12] |
| Human primary fibroblasts                     | Plasma needle | Lazović et al. [13] |
| TK6 cells (B lymphoblastoid cells)            | kINPen         | Bekeschus et al. [14] |
| HaCaT cells (human keratinocyte cells)        | kINPen         | Gaut et al. [15] |
| MCF-10A (human breast epithelial cells)       | DBD             | Schmidt et al. [16] |
| Highly malignant line in vitro                |                 |                 |
| A549 (lung adenocarcinoma)                    | Soft jet plasma | Kaushik et al. [12] |
| T98G (glioblastoma)                           | Soft jet plasma | Kaushik et al. [12] |
| U87MG (glioblastoma)                          | Jet plasma     | Gjika et al. [18] |
| MSK QLL1, SCC1483, SCC15, and SCC25 (squamous cell carcinoma) | Jet plasma | Chang et al. [19] |
| SCC25 (squamous cell carcinoma)               | Jet plasma     | Han et al. [20] |
| Mel (melanoma)                                | miniFlat-PlaSter | Arndt et al. [21] |
| SK-MEL 28 (melanoma)                          | kINPen         | Sagwal et al. [22] |
| A549 (lung adenocarcinoma)                    | DBD             | Karki et al. [23] |
| A2058 (melanoma)                              | DBD             | Sensing et al. [24] |
| B16F10 (melanoma)                             | DBD             | Kim et al. [25] |
| HCT116 (colon carcinoma)                      | DBD             | Judée et al. [26] |
| Tissue ex vivo                                 |                 |                 |
| Human skin                                    | (mini)Flat-PlaSter | Isbary et al. [29] |
| Human oral mucosa                             | kINPen MED      | Hasse et al. [30] |
| Porcine skin                                  | DBD             | Wu et al. [31] |
in the nucleus [39, 175]. In addition, the classification of Kalghatgi and colleagues of cold plasma-induced H2A.X phosphorylation being ATR-dependent and ATM-independent is contestable [17]. ATM is a decerphorox-modulated regulator in the signal cascade upstream of H2A.X phosphorylation. While the kinase is phosphorylated at serine in response to a DSB, oxidized ATM acts as an active homodimer via covalent intermolecular disulfide bridge to cysteine, so that ATM has a dual function: it is active towards both DSB and oxidative stress [37, 60].

The evaluation of the cold plasma effects increasingly focuses on ROS/RNS, which perform their function as cellular signaling molecules or cell-damaging radicals depending on the concentration and localization [85]. Moreover, intracellular changes in the redox system are suggested as a significant event during signal transduction of apoptosis [176]. Equally crucial as directly induced cell death triggered by excessive oxidation of proteins, lipids, or nucleic acids is the potential of ROS to regulate the pathways initiated by other apoptotic stimuli. Particularly, ROS type and source influence the intensity of oxidative stress. It is understood that low ROS levels are agents of redox signaling [177–179]. Furthermore, the redox-sensitive caspases (cysteine-dependent-aspargate-specific proteases) and the stress-sensitive MAPK—p38 and JNK—are decoded regulators upstream of the p38A.X induction [49, 180, 181]. In agreement with this, pharmacological inhibition of oxidative stress signaling pathways by, e.g., SB202190 (p38-MAPK inhibitor) and the apoptosis inhibition via Z-VAD-FMK (pan-caspase inhibitor) significantly neutralized the ROS-triggered but not the UV-induced increase in the p38A.X levels [14], indicating a strong dependence of the p38A.X induction on the p38-MAPK signal and the caspase activation. Accordingly, with regard to the occurrence of phosphorylated H2A.X after cold plasma-derivated ROS/RNS, redox-regulated mediators and mitochondria are presented as intracellular interfaces between ROS and apoptosis signaling pathways [182, 183]. As indicated by Hampton and colleagues two decades ago, intracellular ROS and apoptosis are dependent on caspase activation [184]. Plasma-generated ROS/RNS, especially H2O2, initiate mitochondria-mediated apoptosis: firstly, by changing the membrane potential and secondly, at the level of mRNA expression through simultaneous up-regulation of H2A.X and proapoptotic genes (Bax) and downregulation of antiapoptotic genes (Bcl-2) leading to caspase activation [12]. It follows that cold plasma triggers the mitochondrial intrinsic apoptosis pathway, which is associated with plasma-induced and redox signaling-associated H2A.X. Furthermore, redox modulation is ascribed to p38-MAPK, whereby its ROS sensitivity is based apparently on both direct and indirect redox regulation [185]. Direct oxidation of cysteine activates the p38 molecule and influences its interaction with upstream MAP kinases. The indirect regulation, mediated by ROS, occurs via redox activation of upstream kinases such as ASK1 (apoptosis signal-regulating kinase 1) via redox-mediated inactivation of inhibitory MAPK phosphatases [186]. The p38-regulated phosphorylation of H2A.X is also involved in the epigenetic regulation of the expression of proapoptotic Bim during apoptosis induced by the tyrosine kinase inhibitor imatinib chronic myeloid leukemia cells [50]. Accordingly, imatinib stimulates p38, which induces H2A.X downstream, whose function in connection with apoptosis is closely related to its phosphorylation at serine[139]. This study by Dong and colleagues even reported that H2A.X expression or the blocking of the p38-MAPK-associated H2A.X phosphorylation by SB202190 sensitizes K562 leukemia cells to apoptosis, which also indicates a central role of H2A.X in cell death signaling.

Irrespective of DSBs and apoptotic DNA fragmentation, yH2A.X induction was observed in conditions of UVC exposure, which is interpreted as a reaction to JNK-mediated phosphorylation of H2A.X [51, 101]. In this constellation, the UVC light-induced phosphorylation represents an early apoptotic process initiated before the CAD-mediated DNA fragmentation. Analogously to the JNK activation by UVC light, p38-MAPK can be oxidized, stimulating the CAD-mediated nucleosomal DNA fragmentation leading to yH2A.X [180]. Moreover, maximal yH2A.X induction has been shown two hours posttreatment and thus before the apoptosis time window and the beginning of intermediate apoptosis stages, in which yH2A.X increases dramatically in the course of DNA fragmentation [48, 187]. An occurrence of the nuclear yH2A.X without DNA damage and apoptotic fragmentation forces the idea of a phosphorylated histone H2A.X that is strongly intertwined in the signaling of cell death [188]. Recent data with cold plasma even assign yH2A.X a central role in the signaling of the antioxidant defense system [16]. H2A.X knockout cells showed an increase in endogenous ROS levels, could not recruit any element of the antioxidative response via the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2), which is typically activated in the cytosol as a result of redox-active species, and were associated with mitochondrial damage [89, 189]. Cold plasma treatment has been shown to trigger the translocation of the activated cytosolic Nrf2 into the nucleus in vitro and in vivo [190, 191]. Therefore, these results put phosphorylated H2A.X in the light of a secondary event of redox and apoptosis signaling rather than a primary consequence of direct short-lived ROS/RNS-induced DNA damage upon cold plasma exposure.

5.3. Suitability of yH2A.X as a Risk Marker in Plasma Medicine. The decades-long hypothesis of a causal relationship that yH2A.X represents a reliable indicator for assessing the DNA damage status and that its presence unambiguously marks DSBs is questioned by more and more studies presenting yH2A.X induction in a more diverse light. Similar to the comet assay as a genotoxic endpoint test, H2A.X phosphorylation does not exclusively indicate DNA lesions but also suggests sensitivity to oxidative stress and apoptosis [192]. In all cases, the phosphorylated H2A.X is a biomarker for DSBs but with clear differentiation in the order in which it occurs. In summary, the cause-effect-consequence relationship of yH2A.X formation is best presented in the following: cold plasma-derived exogenous ROS (cause) mediate intracellular oxidative stress that induced apoptosis (effect)
Figure 5: Synopsis of the current understanding of the molecular mechanisms of cold physical plasma effects and the γH2A.X induction in the DDR. A plasma jet generates ROS/RNS in the liquid phase around the cell ①. Aquaporins facilitate the limited ROS/RNS passage across the cell membrane ②. Plasma increases the cytosolic ROS concentration and exposes the cell to oxidative stress, which the intracellular antioxidant system senses ③. By activating mitogen-activated protein kinases (MAPK) and increasing the tumor suppressor protein p53, ROS lead to increased expression of the proapoptotic Bax and cold plasma-induced changes in the mitochondrial membrane potential ΔΨm, initiating the intrinsic apoptosis pathway ④. Plasma-generated ROS also trigger ER stress, which forces mitochondrial disintegration and increased calcium ⑤. In contrast to plasma, UVB light generates ROS intra- and extracellularly. The direct target of UV and ionizing radiation is DNA. While UVB rays induce single-strand breaks (SSBs) ⑥, IR leads to double-strand breaks (DSBs) ⑦. The DNA damage response elements are PI3 kinases; ATR is associated with SSBs, ATM, and DNA-PKcs are associated with DSBs. All three kinases induce the phosphorylation of the nuclear H2A.X to γH2A.X ⑧. In the current understanding, the plasma-induced DDR, including the activation of PI3 kinases and H2A.X, is not a direct plasma effect on the DNA but rather a consequence of plasma-induced redox signaling and apoptosis ⑨.

whereby the phosphorylated H2A.X marks the secondary DSBs during CAD-mediated DNA fragmentation (consequence). However, this causal chain does not have unlimited coherence. Based on the observation that untreated cells already express the phosphorylated histone at a basal level, the presence of γH2A.X in cells exposed to low-dose oxidative stressors could be interpreted and discussed as a protective entity of antioxidant defense. Without having a long-term toxic effect on the genome, low ROS concentrations (cause) enable the efficiency of repair mechanisms (consequence), which is supported by γH2A.X (effect) [37]. By contrast, increased agent-induced (cause) intracellular γH2A.X levels (effect) might make a cell more sensitive to apoptosis (consequence), and it could have a suppressive effect on the (malignant) transformation of the cell. The γH2A.X assay appears to be less valid for the specific DSB detection and clarification of molecular mechanisms potentially acting via DNA damage, as the phosphorylated H2A.X represents a DDR biomarker of the first generation. As a biosensor of pre-cancerous lesions, tumor processes, and progression, and as a predictor of antitumor therapy efficacy, phosphorylated H2A.X has great potential in prevention, diagnostic, therapy evaluation, and outcome [82, 105]. It can be assumed that oxidative stress promotes tumorigenesis through ROS-mediated proliferation and invasion as well as through endogenous chronic ROS-induced oxidative DNA damage, which could be potentially mapped by increased γH2A.X level as an indicator of genomic instability [193, 194]. However, chronic oxidative stress due to a lack of Nrf2-mediated antioxidant response reduces the H2A.X level through protein degradation, which in turn prevents the normal accumulation of γH2A.X after acute stress [195], making cells more sensitive to cytotoxic and antitumor agents. Yet, this study could not conclude that γH2A.X levels are feasible
in risk assessment. Overall, this aligns with another observation showing a clear correlation of γH2A.X and cytotoxicity towards 24 different compounds irrespective of their nature being reportedly mutagenic or nonmutagenic [196]. Consequently, γH2A.X measurements in medical fields and particularly plasma medical research require a careful interpretation of the pleiotropic character of that molecule, including its role in sensing changes in redox homeostasis and apoptotic signaling pathways, are considered and integrated. A mechanistic model is given in Figure 5. Ultimately, γH2A.X does not represent a valid marker for risk assessment in plasma medicine.

6. Conclusion

Contrary to treatment with cold plasma, ionizing and UVB radiation-induced γH2A.X is the result of primarily damaged DNA. While the formation of DSB-related micronuclei as genotoxic markers correlates with the nuclear γH2A.X induction for ionizing and UVB radiation but not for cold plasma, plasma but not IR or UVB-light-induced γH2A.X depends on redox-regulated signaling pathways, apoptosis, and caspase activation. IR and UVB act directly on the DNA, after which phosphorylated H2A.X is recruited as part of the DDR, and irreparably damaged DNA promotes apoptosis. However, plasma-derived exogenous and low-dose ROS without sustained genotoxic effects lead to γH2A.X. Consequently, histone H2A.X phosphorylation on serine 139 initially an indicator of DSBs, does not indicate primarily plasma-induced DNA damage. Physical plasma exerts its biomedical effect through the extracellular release of ROS/RNS, which diffuse intracellularly to exert oxidative stress and induce apoptosis, rather than directly damaging the DNA. Hence, γH2A.X is not the cause but the consequence of cold plasma-induced apoptosis and possibly a protective mechanism to react to oxidative stress and proapoptotic signaling. Due to its pleiotropic roles apart from the DDR and its interlacing action in redox sensing and signaling pathways of apoptosis, phosphorylated H2A.X is less suitable as a risk marker of DSBs in plasma medicine specifically and putatively other medical fields in general.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

This study was funded by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung (BMBF), grant number 03Z22DN11) and the Gerhard-Domagk-Foundation Greifswald, Germany.

References

[1] A. Sharma, K. Singh, and A. Almasan, "Histone h2ax phosphorylation: a marker for DNA damage," in DNA Repair Protocols, L. Bjergbaek, Ed., vol. 920 of Methods in Molecular Biology (Methods and Protocols), pp. 613–626, Humana Press, Totowa, NJ, 2012.

[2] L. J. Mah, A. El-Osta, and T. C. Karagiannis, “γH2AX: a sensitive molecular marker of DNA damage and repair,” Leukemia, vol. 24, no. 4, pp. 679–686, 2010.

[3] A. Takeiri, K. Matsuzaki, S. Motoyama et al., “High-content imaging analyses of γH2AX-foci and micronuclei in tk6 cells elucidated genotoxicity of chemicals and their clastogenic/aneugenic mode of action,” Genes and Environment, vol. 41, no. 1, p. 4, 2019.

[4] D. Yan, J. H. Sherman, and M. Keidar, “Cold atmospheric plasma, a novel promising anti-cancer treatment modality,” Oncotarget, vol. 8, no. 9, pp. 15977–15995, 2017.

[5] G. Pasqual-Melo, R. K. Gandhirajan, I. Stoffels, and S. Bekeschus, “Targeting malignant melanoma with physical plasmas,” Clinical Plasma Medicine, vol. 10, pp. 1–8, 2018.

[6] A. Dubuc, P. Monsarrat, F. Virard et al., “Use of cold-atmospheric plasma in oncology: a concise systematic review,” Therapeutic Advances in Medical Oncology, vol. 10, p. 175883591878647, 2018.

[7] T. von Woedtke, S. Reuter, K. Masur, and K. D. Weltmann, “Plasmas for medicine,” Physics Reports, vol. 530, pp. 291–320, 2013.

[8] S. Bekeschus, A. Schmidt, K.-D. Weltmann, and T. von Woedtke, “The plasma jet kinpen – a powerful tool for wound healing,” Clinical Plasma Medicine, vol. 4, pp. 19–28, 2016.

[9] H.-R. Metelmann, C. Seebauer, V. Miller et al., “Clinical experience with cold plasma in the treatment of locally advanced head and neck cancer,” Clinical Plasma Medicine, vol. 9, pp. 6–13, 2018.

[10] M. Wirtz, I. Stoffels, J. Dissemond, D. Schadendorf, and A. Roesch, “Actinic keratoses treated with cold atmospheric plasma,” Journal of the European Academy of Dermatology and Venereology, vol. 32, no. 1, pp. e37–e39, 2018.

[11] M. Arisi, S. Soglia, E. Guasco Pisani et al., “Cold atmospheric plasma (cap) for the treatment of actinic keratosis and skin field cancerization: clinical and high-frequency ultrasound evaluation,” Dermatology and Therapy, vol. 11, no. 3, pp. 855–866, 2021.

[12] N. Kaushik, N. Uddin, G. B. Sim et al., “Responses of solid tumor cells in dmem to reactive oxygen species generated by non-thermal plasma and chemically induced ros systems,” Scientific Reports, vol. 5, p. 8587, 2015.

[13] S. Lazovic, D. Maletic, A. Leskovac et al., “Plasma induced DNA damage: comparison with the effects of ionizing radiation,” Applied Physics Letters, vol. 105, no. 12, article 124101, 2014.

[14] S. Bekeschus, C. S. Schütz, F. Niefner et al., “Elevated H2AX phosphorylation observed with kinpen plasma treatment is not caused by ROS-mediated DNA damage but is the consequence of apoptosis,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 8535163, 15 pages, 2019.

[15] N. Gaur, H. Kurita, J. S. Oh et al., “On cold atmospheric-pressure plasma jet induced DNA damage in cells,” Journal of Physics D: Applied Physics, vol. 54, no. 3, article 035203, 2021.

[16] A. Schmidt, S. Bekeschus, K. Janick, S. Hasse, T. von Woedtke, and K. Wende, “Cold physical plasma modulates p53 and mitogen-activated protein kinase signaling in keratinocytes,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 7017363, 16 pages, 2019.
X. Han, M. Klas, Y. Y. Liu, M. S. Stack, and S. Ptasinska, “DNA damage in oral cancer cells induced by nitrogen atmospheric plasma pressure jets,” Applied Physics Letters, vol. 102, no. 23, p. 237303, 2013.

S. Arnott, E. Wacker, Y. F. Li et al., “Cold atmospheric plasma, a new strategy to induce senescence in melanoma cells,” Experimental Dermatology, vol. 22, pp. 284–289, 2013.

S. K. Sagwal, G. Pasqual-Melo, Y. Bodnar, R. K. Gandhirajran, and S. Bekeschus, “Combination of chemotherapy and physical plasma elicits melanoma cell death via upregulation of SLC22A16,” Cell Death & Disease, vol. 9, article e1179, 2018.

S. B. Karki, T. T. Gupta, E. Yildirim-Ayan, K. M. Eisenmann, and H. Ayan, “Miniature non-thermal plasma induced cell cycle arrest and apoptosis in lung carcinoma cells,” Plasma Chemistry and Plasma Processing, vol. 40, pp. 99–117, 2020.

R. Sensenig, S. Kalghatgi, E. Cerchar et al., “Non-thermal plasma induces apoptosis in melanoma cells via production of intracellular reactive oxygen species,” Annals of Biomedical Engineering, vol. 39, pp. 674–687, 2011.

G. J. Kim, W. Kim, K. T. Kim, and J. K. Lee, “DNA damage and mitochondria dysfunction in cell apoptosis induced by nonthermal air plasma,” Applied Physics Letters, vol. 96, article 021502, 2010.

F. Judee, C. Fongia, B. Ducommun, M. Yousfi, V. Lobjois, and N. Merbah, “Short and long time effects of low temperature plasma activated media on 3D multicellular tumor spheroids,” Scientific Reports, vol. 6, p. 21421, 2016.

J. M. Plewa, M. Yousfi, C. Fongia et al., “Low-temperature plasma-induced antiproliferative effects on multi-cellular tumor spheroids,” New Journal of Physics, vol. 16, article 043027, 2014.

J. S. Choi, J. Kim, Y. J. Hong et al., “Evaluation of non-thermal plasma-induced anticancer effects on human colon cancer cells,” Biomedical Optics Express, vol. 8, pp. 2649–2659, 2017.

G. Isbary, J. Köritzer, A. Mitra et al., “Ex vivo human skin experiments for the evaluation of safety of new cold atmospheric plasma devices,” Clinical Plasma Medicine, vol. 1, pp. 36–44, 2013.

S. Hasse, O. Hahn, S. Kindler, T. Woerdke, H. R. Metelmam, and K. Masur, “Atmospheric pressure plasma jet application on human oral mucosa modulates tissue regeneration,” Plasma Medicine, vol. 4, no. 1-4, pp. 117–129, 2014.

A. S. Wu, S. Kalghatgi, D. Dobrynin et al., “Porcine intact and wounded skin responses to atmospheric nonthermal plasma,” Journal of Surgical Research, vol. 179, no. 1, pp. e1–e12, 2013.

E. Gjika, S. Pal-Ghosh, M. E. Kirschner et al., “Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of u87MG glioblastoma cells,” Scientific Reports, vol. 10, no. 1, article 16495, 2020.

J. W. Chang, S. U. Kang, Y. S. Shin et al., “GammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization,” Cell Cycle, vol. 9, pp. 662–669, 2010.

E. M. Hanschmann, J. R. Godoy, C. Berndt, C. Hudemann, and C. H. Lillig, “Thioredoxins, glutaredoxins, and peroxiredoxins–molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling,” Antioxidants & Redox Signaling, vol. 19, pp. 1539–1605, 2013.

D. Pruss, J. J. Hayes, and A. P. Wolffe, “Nucleosomal anatomy–where are the histones?,” BioEssays, vol. 17, pp. 161–170, 1995.

K. Lugher, A. W. Mader, R. K. Richmond, D. F. Sargent, and T. J. Richmond, “Crystal structure of the nucleosome core particle at 2.8 Å resolution,” Nature, vol. 389, pp. 251–260, 1997.

C. Mannironi, W. M. Bonner, and C. L. Hatch, “A histone isoform with a conserved c-terminal sequence, is encoded by a novel mRNA with both DNA replication type and polyA 3’ processing signals,” Nucleic Acids Research, vol. 17, pp. 9113–9126, 1989.

A. Kinner, W. Wu, C. Staudt, and G. Ilakis, “Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin,” Nucleic Acids Research, vol. 36, pp. 5678–5694, 2008.

R. K. Singh, J. Paik, and A. Gunjan, “Generation and management of excess histones during the cell cycle,” Frontiers in Bioscience, vol. 14, pp. 3145–3158, 2009.
Oxidative Medicine and Cellular Longevity

Current Opinion in Genetics & Development, vol. 12, pp. 162–169, 2002.

[47] T. Stiff, M. O’Driscoll, N. Rief, K. Iwabuchi, M. Lobrich, and P. A. Jeggo, “Atm and DNA-pk function redundantly to phosphorylate H2AX after exposure to ionizing radiation,” Cancer Research, vol. 64, pp. 2390–2396, 2004.

[48] S. Hanasoge and M. Ljungman, “H2AX phosphorylation after uv irradiation is triggered by DNA repair intermediates and is mediated by the ATR kinase,” Carcinogenesis, vol. 28, pp. 2298–2304, 2007.

[49] J. S. Chiu, J. I. Chao, Y. J. Lee, and T. S. Hsu, “Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells,” Toxicology Letters, vol. 179, pp. 63–70, 2008.

[50] Y. Dong, M. Xiong, L. Duan et al., “H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib,” Apoptosis, vol. 19, pp. 1281–1292, 2014.

[51] H. K. Sluss and R. J. Davis, “H2AX is a target of the jnk signaling pathway that is required for apoptotic DNA fragmentation,” Molecular Cell, vol. 23, pp. 152–153, 2006.

[52] X. Li, A. Nan, Y. Xiao, Y. Chen, and Y. Lai, “PP2A-B56 complex is involved in dephosphorylation of gamma-H2AX in the repair process of CPT-induced DNA double-strand breaks,” Toxicology, vol. 331, pp. 57–65, 2015.

[53] W. Z. Tu, B. Li, B. Huang et al., “GammaH2AX foci formation in the absence of DNA damage: mitotic H2AX phosphorylation is mediated by the DNA-PKcs/CHK2 pathway,” FEBs Letters, vol. 587, pp. 3437–3443, 2013.

[54] J. Bartkova, Z. Horejsi, K. Koed et al., “DNA damage response as a candidate anti-cancer barrier in early human tumorgenesis,” Nature, vol. 434, no. 7035, pp. 864–870, 2005.

[55] S. Sudhir Ambekar, S. S. Hattur, and P. B. D. N. A. Bule, “DNA: Damage and repair mechanisms in humans,” Global Journal of Pharmacy & Pharmaceutical Sciences, vol. 3, no. 3, 2017.

[56] T. T. Paull, E. P. Rogakou, V. Yamazaki, C. U. Kirchgessner, M. Gellert, and W. M. Bonner, “A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage,” Current Biology, vol. 10, pp. 886–895, 2000.

[57] J. Kang, D. Ferguson, H. Song et al., “Functional interaction of H2AX, NBS1, and p53 in ataxia-telangiectasia DNA damage responses and tumor suppression,” Molecular and Cellular Biology, vol. 25, pp. 661–670, 2005.

[58] L. Zou and S. J. Elledge, “Sensing DNA damage through ataxia telangiectasia and DNA damage checkpoints,” Science, vol. 300, pp. 1542–1548, 2003.

[59] J. Sancar, L. A. Lindsey-Boltz, K. Uswal-Kacmaz, and S. Linn, “Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints,” Annual Review of Biochemistry, vol. 73, pp. 39–85, 2004.

[60] Z. Guo, S. Kozlov, M. F. Lavin, M. D. Person, and T. T. Paull, “ATM activation by oxidative stress,” Science, vol. 330, pp. 517–521, 2010.

[61] P. Davalli, G. Marverty, A. Lauriola, and D. D’Arca, “Targeting oxidatively induced DNA damage response in cancer: opportunities for novel cancer therapies,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 2389523, 21 pages, 2018.

[62] W. M. Bonner, C. E. Redon, J. S. Dickey et al., “GammaH2AX and cancer,” Nature Reviews. Cancer, vol. 8, pp. 957–967, 2008.

[63] D. P. Johnson, M. B. Chandrasekharan, M. Dutreix, and S. Bhaskara, “Targeting DNA repair and chromatin crosstalk in cancer therapy,” Cancers, vol. 13, 2021.

[64] K. K. Khanna and S. P. Jackson, “DNA double-strand breaks: signaling, repair and the cancer connection,” Nature Genetics, vol. 27, pp. 247–254, 2001.

[65] N. C. House, M. R. Koch, and C. H. Freudentreich, “Chromatin modifications and DNA repair: beyond double-strand breaks,” Frontiers in Genetics, vol. 5, p. 296, 2014.

[66] J. P. Banath and P. L. Olive, “Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks,” Cancer Research, vol. 63, no. 15, pp. 4347–4350, 2003.

[67] T. Tanaka, X. Huang, E. Jorgensen et al., “ATM activation accompanies histone H2AX phosphorylation in A549 cells upon exposure to tobacco smoke,” BMC Cell Biology, vol. 8, p. 26, 2007.

[68] G. P. Watters, D. J. Smart, J. S. Harvey, and C. A. Austin, “H2AX phosphorylation as a genotoxicity endpoint,” Mutation Research, vol. 679, no. 1-2, pp. 50–58, 2009.

[69] F. Zhang and Z. Gong, “Regulation of DNA double-strand break repair pathway choice: a new focus on 53BP1,” Journal of The Chinese University. Science. B, vol. 22, pp. 38–46, 2021.

[70] A. N. Osipov, M. Pustovalova, A. Grekhova et al., “Low doses of X-rays induce prolonged and atm-independent persistence of γH2AX foci in human gingival mesenchymal stem cells,” Oncotarget, vol. 6, no. 29, pp. 27275–27287, 2015.

[71] S. Kawashima, N. Kawaguchi, K. Taniguchi et al., “γ-H2AX as a potential indicator of radiosensitivity in colorectal cancer cells,” Oncology Letters, vol. 20, no. 3, pp. 2331–2337, 2020.

[72] H. D. Halicka, X. Huang, F. Traganos, M. A. King, W. Dai, and Z. Darzynkiewicz, “Histone H2AX phosphorylation after cell irradiation with UV-B: relationship to cell cycle phase and induction of apoptosis,” Cell Cycle, vol. 4, pp. 338–344, 2005.

[73] H. Xiao, T. K. Li, J. M. Yang, and L. F. Liu, “Acidic phosphatase induces topoisomerase II-mediated DNA damage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, pp. 5205–5210, 2003.

[74] H. Kaneko, K. Igarashi, K. Kataoka, and M. Miura, “Heat shock induces phosphorylation of histone H2AX in mammalian cells,” Biochemical and Biophysical Research Communications, vol. 328, pp. 1101–1106, 2005.

[75] J. Williamson, C. M. Hughes, G. Burke, and G. W. Davison, “A combined gamma-H2AX and 53BP1 approach to determine the DNA damage-repair response to exercise in hypoxia,” Free Radical Biology & Medicine, vol. 154, pp. 9–17, 2020.

[76] L. A. Parsels, J. D. Parsels, D. M. Tanska, J. Maybaum, T. S. Ewald, D. Sampath, and W. Plunkett, “H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation,” Molecular Cancer Therapeutics, vol. 6, no. 4, pp. 1239–1248, 2007.
[78] E. P. Rogakou, W. Nieves-Neira, C. Boon, Y. Pommier, and W. M. Bonner, “Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139,” The Journal of Biological Chemistry, vol. 275, pp. 9390–9395, 2000.

[79] O. A. Sedelnikova, I. Horikawa, D. B. Zimonjic, N. C. Popescu, W. M. Bonner, and J. C. Barrett, “Senescing human cells and ageing mice accumulate DNA lesions with unreparable double-strand breaks,” Nature Cell Biology, vol. 6, pp. 168–170, 2004.

[80] O. Fernandez-Capetillo, S. K. Mahadevaih, A. Celeste et al., “H2ax is required for chromatin remodeling and inactivation of sex chromosomes in male mouse meiosis,” Developmental Cell, vol. 4, pp. 497–508, 2003.

[81] V. V. Palla, G. Karaolanis, I. Katafijotis et al., “Gamma-H2AX: can it be established as a classical cancer prognostic factor?,” Tumour Biology, vol. 39, no. 3, 2017.

[82] P. V. Varvara, G. Karaolanis, C. Valavanis et al., “Gamma-H2AX: a potential biomarker in breast cancer,” Tumour Biology, vol. 41, 2019.

[83] A. Georgoulis, C. E. Vorgias, G. P. Chrousos, and E. P. Rogakou, “Genome instability and H2AX,” International Journal of Molecular Sciences, vol. 18, no. 9, 2017.

[84] A. Celeste, O. Fernandez-Capetillo, M. J. Kruhlak et al., “Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks,” Nature Cell Biology, vol. 5, pp. 675–679, 2003.

[85] M. A. Kang, E. Y. So, A. L. Simons, D. R. Spitz, and T. Ouchi, “DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway,” Cell Death & Disease, vol. 3, 2012.

[86] Y. T. Magalhaes, J. O. Farias, L. E. Silva, and F. L. Forti, “GTPases, genome, actin: a hidden story in DNA damage response and repair mechanisms,” DNA Repair, vol. 100, 2021.

[87] P. Rybak, A. Hoang, L. Bujnowicz et al., “Low level phosphorylation of histone H2AX on serine 139 (γH2AX) is not associated with DNA double-strand breaks,” Oncotarget, vol. 7, no. 31, pp. 49574–49587, 2016.

[88] Y. Ichijima, R. Sakasai, N. Okita, K. Asahina, S. Mizutani, and H. Teraoka, “Phosphorylation of histone H2AX at M phase in human cells without DNA damage response,” Biochemical and Biophysical Research Communications, vol. 336, pp. 807–812, 2005.

[89] J. H. Jeong, Y. Cheol Kang, Y. Piao, S. Kang, and Y. K. Pak, “miR-24-mediated knockdown of H2AX damages mitochondria and the insulin signaling pathway,” Experimental & Molecular Medicine, vol. 49, 2017.

[90] T. Tanaka, X. Huang, H. D. Halicka et al., “Cytometry of atm activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents,” Cytometry. Part A, vol. 71A, no. 9, pp. 648–661, 2007.

[91] E. P. Rogakou, D. R. Pilch, A. H. Orr, V. S. Ivanova, and W. M. Bonner, “DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139,” The Journal of Biological Chemistry, vol. 273, pp. 5858–5868, 1998.

[92] H. V. Goutham, K. D. Mumbrekar, B. M. Vadhiraja et al., “Double-strand break analysis by gamma-H2AX foci: a useful method for determining the overreactors to radiation-induced acute reactions among head-and-neck cancer patients,” International Journal of Radiation Oncology • Biology • Physics, vol. 84, pp. e607–e612, 2012.

[93] S. Burma, B. P. Chen, M. Murphy, A. Kurimasa, and D. J. Chen, “ATM phosphorylates histone H2AX in response to DNA double-strand breaks,” The Journal of Biological Chemistry, vol. 276, pp. 42462–42467, 2001.

[94] D. Firsanov, A. Vasilishina, A. Kropotov, and V. Mikhailov, “Dynamics of gammaH2AX formation and elimination in mammalian cells after X-irradiation,” Biochimie, vol. 94, pp. 2416–2422, 2012.

[95] K. Rothkamm, S. Barnard, J. Moquet, M. Ellender, Z. Rana, and S. Burdak-Rothkamm, “DNA damage foci: meaning and significance,” Environmental and Molecular Mutagenesis, vol. 56, pp. 491–504, 2015.

[96] T. Yu, S. H. MacPhail, J. P. Banath, D. Klokow, and P. L. Olive, “Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability,” DNA Repair, vol. 5, pp. 935–946, 2006.

[97] J. P. Banath, S. H. MacPhail, and P. L. Olive, “Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines,” Cancer Research, vol. 64, pp. 7144–7149, 2004.

[98] A. I. Nakamura, C. E. Redon, W. M. Bonner, and O. A. Sedelnikova, “Telomere-dependent and telomere-independent origins of endogenous DNA damage in tumor cells,” Aging, vol. 1, no. 2, pp. 212–218, 2009.

[99] D. M. Pinto and A. Flaus, “Structure and function of histone H2AX,” Sub-Cellular Biochemistry, vol. 50, pp. 55–78, 2010.

[100] A. I. Nakamura, V. A. Rao, Y. Pommier, and W. M. Bonner, “The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks,” Cell Cycle, vol. 9, pp. 389–397, 2010.

[101] S. de Feraudy, I. Revet, V. Bezrokoove, L. Feeney, and J. E. Cleaver, “A minority of foci or pan-nuclear apoptotic staining of gammaH2AX in the S phase after UV damage contain DNA double-strand breaks,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, pp. 6870–6875, 2010.

[102] N. Taneja, M. Davis, J. S. Choy et al., “Histone H2AX Phosphorylation as a Predictor of Radiosensitivity and Target for Radiotherapy,” The Journal of Biological Chemistry, vol. 279, no. 3, pp. 2273–2280, 2004.

[103] E. Moeglin, D. Desplanq, S. Conic et al., “Uniform widespread nuclear phosphorylation of histone H2AX is an indicator of lethal DNA replication stress,” Cancers, vol. 11, no. 3, 2019.

[104] Y. Lee, Q. Wang, I. Shuryak, D. J. Brenner, and H. C. Turner, “Development of a high-throughput gamma-H2AX assay based on imaging flow cytometry,” Radiation Oncology, vol. 14, p. 150, 2019.

[105] O. A. Sedelnikova and W. M. Bonner, “GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence,” Cell Cycle, vol. 5, pp. 2909–2913, 2006.

[106] K. Khan, S. Tewari, N. P. Awasthi et al., “Flow cytometric detection of gamma-H2AX to evaluate DNA damage by low dose diagnostic irradiation,” Medical Hypotheses, vol. 115, pp. 22–28, 2018.

[107] P. L. Olive and J. P. Banath, “Phosphorylation of histone H2AX as a measure of radiosensitivity,” International Journal of Radiation Oncology • Biology • Physics, vol. 58, pp. 331–335, 2004.
[108] L. G. Mariotti, G. Pirovano, K. I. Savage et al., “Use of the gamma-H2AX assay to investigate DNA repair dynamics following multiple radiation exposures,” PLoS One, vol. 8, 2013.

[109] S. Schumann, U. Eberlein, R. Muhtadi, M. Lassmann, and H. Scherthan, “DNA damage in leukocytes after internal ex- vivo irradiation of blood with the alpha-emitter Ra-223,” Scientific Reports, vol. 8, 2018.

[110] A. Stenvall, E. Larsson, B. Holmqvist, S. E. Strand, and B. A. Jonsson, “Quantitative γ-H2AX immunofluorescence method for DNA double-strand break analysis in testis and liver after intravenous administration of 111InCl3,” EJ/NMML Research, vol. 10, no. 1, 2020.

[111] I. V. Mavragani, Z. Nikitaki, S. A. Kalospyros, and A. G. Georgakilas, “Ionizing radiation and complex DNA damage: from prediction to detection challenges and biological significance,” Cancers, vol. 11, no. 11, p. 1789, 2019.

[112] K. Kawamura, F. Qi, and J. Kobayashi, “Potential relationship between the biological effects of low-dose irradiation and mitochondrial ROS production,” Journal of Radiation Research, vol. 59, Supplement 2, pp. i91–i97, 2018.

[113] E. I. Azzam, J. P. Jay-Gerin, and D. Pain, “Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury,” Cancer Letters, vol. 327, pp. 48–60, 2012.

[114] S. Dong, X. Lyu, S. Yuan et al., “Oxidative stress: a critical hint in ionizing radiation induced pyroptosis,” Radiation Medicine and Protection, vol. 1, no. 4, pp. 179–185, 2020.

[115] R. X. Huang and P. K. Zhou, “DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer,” Signal Transduction and Targeted Therapy, vol. 5, no. 1, p. 60, 2020.

[116] D. Bettega, P. Calzolari, L. Doneda, F. Belloni, L. Tallone, and J. L. Redpath, “Differential effectiveness of solar uvb subcomponents in causing cell death, oncogenic transformation and micronuclear induction in human hybrid cells,” International Journal of Radiation Biology, vol. 79, no. 3, pp. 211–216, 2003.

[117] A. Budiyanto, N. U. Ahmed, A. Wu et al., “Protective effect of topically applied olive oil against photocarcinogenesis following UVB exposure of mice,” Carcinogenesis, vol. 21, pp. 2085–2090, 2000.

[118] T. Herrling, K. Jung, and J. Fuchs, “Measurements of UV-generated free radicals/reactive oxygen species (ROS) in skin,” Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, vol. 63, no. 4, pp. 840–845, 2006.

[119] A. Privat-Maldonado, A. Schmidt, A. Lin et al., “ROS from physical plasmas: redox chemistry for biomedical therapy,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 9062098, 29 pages, 2019.

[120] H. Tresp, M. U. Hammer, J. Winter, K. D. Weltmann, and S. Reuter, “Quantitative detection of plasma-generated radicals in liquids by electron paramagnetic resonance spectroscopy,” Journal of Physics D: Applied Physics, vol. 46, no. 43, p. 435401, 2013.

[121] A. Schmidt-Bleker, J. Winter, A. Bosel, S. Reuter, and K. D. Weltmann, “On the plasma chemistry of a cold atmospheric argon plasma jet with shielding gas device,” Plasma Sources Science and Technology, vol. 25, 2016.

[122] H. Jablonowski, A. Schmidt-Bleker, K. D. Weltmann, T. von Woedtke, and K. Wende, “Non-touching plasma-liquid interaction - where is aqueous nitric oxide generated?,” Physical Chemistry Chemical Physics, vol. 20, no. 39, pp. 25387–25398, 2018.

[123] D. B. Graves, “The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology,” Journal of Physics D: Applied Physics, vol. 45, no. 26, 2012.

[124] W. V. Gaens, S. Iseni, A. Schmidt-Bleker, K. D. Weltmann, S. Reuter, and A. Bogaerts, “Numerical analysis of the effect of nitrogen and oxygen admixtures on the chemistry of an argon plasma jet operating at atmospheric pressure,” New Journal of Physics, vol. 17, 2015.

[125] A. Fridman, A. Chirokov, and A. Gutsol, “Non-thermal atmospheric pressure discharges,” Journal of Physics D: Applied Physics, vol. 38, pp. R1–R24, 2005.

[126] H. Jablonowski and T. von Woedtke, “Research on plasma medicine-relevant plasma-liquid interaction: What happened in the past five years?,” Clinical Plasma Medicine, vol. 3, no. 2, pp. 42–52, 2015.

[127] R. Brandenburg, “Dielectric barrier discharges: progress on plasma sources and on the understanding of regimes and single filaments,” Plasma Sources Science and Technology, vol. 26, 2017.

[128] J. Winter, R. Brandenburg, and K. D. Weltmann, “Atmospheric pressure plasma jets: an overview of devices and new directions,” Plasma Sources Science and Technology, vol. 24, 2015.

[129] S. Bekeschus, J. Kolata, C. Winterbourn et al., “Hydrogen peroxide: a central player in physical plasma-induced oxidative stress in human blood cells,” Free Radical Research, vol. 48, pp. 542–549, 2014.

[130] H. Jablonowski, J. Santos Sousa, K. D. Weltmann, K. Wende, and S. Reuter, “Quantification of the ozone and singlet delta oxygen produced in gas and liquid phases by a non-thermal atmospheric plasma with relevance for medical treatment,” Scientific Reports, vol. 8, 2018.

[131] S. Bekeschus, T. von Woedtke, A. Kramer, K.-D. Weltmann, and K. Masur, “Cold physical plasma treatment alters redox balance in human immune cells,” Plasma Medicine, vol. 3, pp. 267–278, 2013.

[132] H. Sies, “Strategies of antioxidant defense,” European Journal of Biochemistry, vol. 215, pp. 213–219, 1993.

[133] T. von Woedtke, A. Schmidt, S. Bekeschus, K. Wende, and K. D. Weltmann, “Plasma medicine: a field of applied redox biology,” In Vivo, vol. 33, 2019.

[134] J. Van der Paal, C. Verheyen, E. C. Neyts, and A. Bogaerts, “Hampering effect of cholesterol on the permeation of reactive oxygen species through phospholipids bilayer: possible explanation for plasma cancer selectivity,” Scientific Reports, vol. 7, 2017.

[135] A. Gorlach, K. Bertram, S. Hudcova, and O. Krizanova, “Calcium and ROS: a mutual interplay,” Redox Biology, vol. 6, pp. 260–271, 2015.

[136] C. Schneider, L. Gebhardt, S. Arndt et al., “Cold atmospheric plasma causes a calcium influx in melanoma cells triggering cap-induced senescence,” Scientific Reports, vol. 8, p. 10048, 2018.

[137] K. Kannan and S. K. Jain, “Effect of vitamin B6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2-treated U937 monocytes,” Free Radical Biology & Medicine, vol. 36, no. 4, pp. 423–428, 2004.

[138] S. Bekeschus, A. Mueller, V. Miller, U. Gaipl, and K.-D. Weltmann, “Physical plasma elicits immunogenic cancer cell death and mitochondrial singlet oxygen,” IEEE...
Transactions on Radiation and Plasma Medical Sciences, vol. 2, no. 2, pp. 138–146, 2018.

[139] M. H. Ruwan Kumara, M. J. Piao, K. A. Kang et al., “Non-thermal gas plasma-induced endoplasmic reticulum stress mediates apoptosis in human colon cancer cells,” Oncology Reports, vol. 36, no. 4, p. 2268–2274, 2016.

[140] A. Raturi and T. Simmen, “Where the endoplasmic reticulum and the mitochondrion tie the knot: the mitochondria-associated membrane (MAM),” Biochimica et Biophysica Acta, vol. 1833, pp. 213–224, 2013.

[141] H. J. Ahn, K. I. Kim, G. Kim, E. Moon, S. S. Yang, and J. S. Lee, “Atmospheric-pressure plasma jet induces apoptosis involving mitochondria via generation of free radicals,” PLoS One, vol. 6, no. 11, article e28154, 2011.

[142] T. von Woedtke, S. Emmert, H.-R. Metelmann, S. Rupf, and K.-D. Weltmann, “Perspectives on cold atmospheric pressure plasma (CAP) applications in medicine,” Physics of Plasmas, vol. 27, no. 7, p. 070601, 2020.

[143] R. Morent, N. De Geyter, T. Desmet, P. Dubruel, and C. Leys, “Plasma surface modification of biodegradable polymers: a review,” Plasma Processes and Polymers, vol. 8, no. 3, pp. 171–190, 2011.

[144] S. Bekeschus, B. Poschkamp, and J. van der Linde, “Medical gas plasma promotes blood coagulation via platelet activation,” Biomaterials, vol. 278, p. 120433, 2021.

[145] T. Bernhardt, M. L. Semmler, M. Schäfer, S. Bekeschus, S. Emmert, and L. Boeckmann, “Plasma medicine: applications of cold atmospheric pressure plasma in dermatology,” Oxidative Medicine and Cellular Longevity, vol. 2019, 2019.

[146] M. Gherardi, R. Tonini, and V. Colombo, “Plasma in dentistry: brief history and current status,” Trends in Biotechnology, vol. 36, no. 6, pp. 583–585, 2018.

[147] H. Nikmaram, M. Rezaei Kanavi, M. Ghoranneviss et al., “Cold atmospheric pressure plasma jet for the treatment of _Aspergillus_ keratitis,” Clinical Plasma Medicine, vol. 9, pp. 14–18, 2018.

[148] C. Seehauer, E. Freund, S. Hasse et al., “Effects of cold physical plasma on oral lichen planus: an in vitro study (effects of CAP on OLP),” Oral Diseases, vol. 27, no. 7, pp. 1728–1737, 2021.

[149] M. L. Semmler, S. Bekeschus, M. Schäfer et al., “Molecular mechanisms of the efficacy of cold atmospheric pressure plasma (CAP) in cancer treatment,” Cancers (Basel), vol. 12, no. 2, p. 269, 2020.

[150] X. Zhou, D. Cai, S. Xiao et al., “InvivoPen: a novel plasma source forin vivocancer treatment,” Journal of Cancer, vol. 11, no. 8, pp. 2273–2282, 2020.

[151] M. Adhikari, B. Adhikari, A. Adhikari et al., “Cold atmospheric plasma as a novel therapeutic tool for the treatment of brain cancer,” Current Pharmaceutical Design, vol. 26, pp. 2195–2206, 2020.

[152] L. Feil, A. Koch, R. Utz et al., “Cancer-selective treatment of cancerous and non-cancerous human cervical cell models by a non-thermally operated electrosurgical argon plasma device,” Cancers (Basel), vol. 12, no. 4, p. 1037, 2020.

[153] J. Tornin, C. Labay, F. Tampieri, M. P. Ginebra, and C. Canal, “Evaluation of the effects of cold atmospheric plasma and plasma-treated liquids in cancer cell cultures,” Nature Protocols, vol. 16, no. 6, pp. 2826–2850, 2021.

[154] S. Bekeschus, G. Liebelt, J. Menz et al., “Tumor cell metabolism correlates with resistance to gas plasma treatment: the evaluation of three dogmas,” Free Radical Biology & Medicine, vol. 167, pp. 12–28, 2021.

[155] M. Khalili, L. Daniels, A. Lin et al., “Non-thermal plasma-induced immunogenic cell death in cancer: a topical review,” Journal of Physics D: Applied Physics, vol. 52, no. 42, p. 423001, 2019.

[156] S. Bekeschus, R. Clemen, and H.-R. Metelmann, “Potentiating anti-tumor immunity with physical plasma,” Clinical Plasma Medicine, vol. 12, pp. 17–22, 2018.

[157] S. Bekeschus, A. Kramer, E. Suffredini, T. von Woedtke, and V. Colombo, “Gas plasma technology-an asset to healthcare during viral pandemics such as the COVID-19 crisis?,” IEEE Trans Radiat Plasma Med Sci, vol. 4, pp. 391–399, 2020.

[158] S. Reuter, T. von Woedtke, and K. D. Weltmann, “The kINPEN-a review on physics and chemistry of the atmospheric pressure plasma jet and its applications,” Journal of Physics D: Applied Physics, vol. 51, 2018.

[159] OECD, T.N.I.V.M.C.M.T.i.s.O.G.f.t.T.o.C., Section 4: health effects, OECD, 2016, 29. Juli.

[160] T. Maisch, A. K. Bosserhoff, P. Unger et al., “Investigation of toxicity and mutagenicity of cold atmospheric argon plasma,” Environmental and Molecular Mutagenesis, vol. 58, no. 3, pp. 172–177, 2017.

[161] H. Lisowska, A. Wegierek-Ciuk, A. Banasik-Nowak et al., “The dose-response relationship for dicentric chromosomes and gamma-H2AX foci in human peripheral blood lymphocytes: influence of temperature during exposure and intra- and inter-individual variability of donors,” International Journal of Radiation Biology, vol. 89, pp. 191–199, 2013.

[162] H. C. Turner, I. Shuryak, M. Taversas et al., “Effect of dose rate on residual gamma-H2AX levels and frequency of micronuclei in x-irradiated mouse lymphocytes,” Radiation Research, vol. 183, pp. 315–324, 2015.

[163] G. P. Bienert, A. L. B. Moller, K. A. Kristiansen et al., “Specific aquaporins facilitate the diffusion of hydrogen peroxide across membranes,” The Journal of Biological Chemistry, vol. 282, pp. 1183–1192, 2007.

[164] T. Kawasaki, S. Kusumegi, A. Kudo et al., “Effects of irradiation distance on supply of reactive oxygen species to the bottom of a petri dish filled with liquid by an atmospheric O2/He plasma jet,” Journal of Applied Physics, vol. 119, 2016.

[165] A. G. Cox, C. C. Winterbourn, and M. B. Hampton, “Mitochondrial peroxiredoxin involvement in antioxidant defence and reduct signalling,” The Biochemical Journal, vol. 425, pp. 313–325, 2009.

[166] M. B. Hampton and K. M. O’Connor, “Peroxiredoxins and the regulation of cell death,” Molecules and Cells, vol. 39, pp. 72–76, 2016.

[167] F. Antunes and E. Cadenas, “Estimation of H2O2 gradients across biomembranes,” FEBS Letters, vol. 475, no. 2, pp. 121–126, 2000.

[168] C. Gu, J. Luo, X. Lu et al., “REV7 confers radioresistance of esophage squamous cell carcinoma by recruiting PRDX2,” Cancer Science, vol. 110, no. 3, pp. 962–972, 2019.

[169] E. Pourcelot, M. Lenon, N. Mobilia et al., “Iron for proliferation of cell lines and hematopoietic progenitors: nailing down the intracellular functional iron concentration,” Biochimie et Biophysica Acta, vol. 1853, no. 7, pp. 1596–1605, 2015.

[170] S. Solier and Y. Pommier, “The nuclear γ-H2AX apoptotic ring: implications for cancers and autoimmune diseases,”
with ionizing radiation,” *Current Science*, vol. 116, pp. 1229–1233, 2019.

[188] M. Weiss, D. Gumbel, E. M. Hanschmann et al., “Cold atmospheric plasma treatment induces anti-proliferative effects in prostate cancer cells by redox and apoptotic signaling pathways,” *PLoS One*, vol. 10, article e0130350, 2015.

[189] U. Weyemi, B. D. Paul, A. M. Snowman et al., “Histone H2AX deficiency causes neurobehavioral deficits and impaired redox homeostasis,” *Nature Communications*, vol. 9, p. 1526, 2018.

[190] A. Schmidt, S. Dietrich, A. Steuer et al., “Non-thermal plasma activates human keratinocytes by stimulation of antioxidant and phase II pathways,” *The Journal of Biological Chemistry*, vol. 290, pp. 6731–6750, 2015.

[191] A. Schmidt, T. von Woedtke, B. Vollmar, S. Hasse, and S. Bekeschus, “Nrf2 signaling and inflammation are key events in physical plasma-spurred wound healing,” *Theranostics*, vol. 9, no. 4, pp. 1066–1084, 2019.

[192] P. Chourcoun, D. Gillet, G. Dorange, B. Sawicki, and J. D. Dewitte, “Comet assay and early apoptosis,” *Mutation Research*, vol. 708, no. 1-2, pp. 89–96, 2001.

[193] J. G. Gill, E. Piskounova, and S. J. Morrison, “Cancer, oxidative stress, and metastasis,” *Cold Spring Harbor Symposium on Quantitative Biology*, vol. 81, pp. 163–175, 2016.

[194] O. A. Sedelnikova, C. E. Redon, J. S. Dickey, A. J. Nakamura, A. G. Georgakilas, and W. M. Bonner, “Role of oxidatively induced DNA lesions in human pathogenesis,” *Mutation Research*, vol. 704, pp. 152–159, 2010.

[195] T. Gruosso, V. Mieulet, M. Cardon et al., “Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients,” *EMBO Molecular Medicine*, vol. 8, pp. 527–549, 2016.

[196] T. Nikolova, M. Dvorak, F. Jung et al., “The γH2AX assay for genotoxic and nongenotoxic agents: comparison of H2AX phosphorylation with cell death response,” *Toxicological Sciences*, vol. 140, no. 1, pp. 103–117, 2014.